Wednesday, March 25, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Analysis

A Defensive Powerhouse: Agree Realty’s Strategic Edge in Net-Lease Investing

Robert Sasse by Robert Sasse
September 18, 2025
in Analysis, Dividends, Real Estate & REITs
0
Agree Realty Stock
0
SHARES
131
VIEWS
Share on FacebookShare on Twitter

While numerous real estate investment trusts face headwinds from interest rate fluctuations, Agree Realty continues to demonstrate remarkable operational resilience. This net-lease specialist, distinguished by its roster of creditworthy tenants, expanding profitability, and an exceptional dividend track record, appears largely insulated from broader market volatility. This analysis examines the core strengths behind this performance and evaluates the investment case at current valuation levels.

Unwavering Financial Performance and Growth Trajectory

The company’s latest quarterly results provide compelling evidence of its financial health. Agree Realty reported an adjusted funds from operations (AFFO) of $1.06 per share, representing a 1.7 percent year-over-year increase. More significantly, management raised its full-year guidance, projecting AFFO between $4.29 and $4.32 per share. This upward revision signals confidence in achieving growth exceeding 4 percent for the period.

Concurrently, the REIT has substantially amplified its investment capacity. The company increased its 2025 investment guidance to a range of $1.4 to $1.6 billion, demonstrating a clear commitment to an aggressive expansion strategy through targeted acquisitions and property development.

Premium Credit Rating and Dividend Aristocrat Status

Few REITs can claim over three decades of consistent dividend distributions. Agree Realty stands among this elite group, having recently increased its monthly payout to $0.256 per share. This adjustment marks a 2.4 percent annual raise for shareholders. The current dividend yield of approximately 4.26 percent remains attractive, particularly when supported by a sustainable payout ratio of about 72-73 percent of AFFO.

Should investors sell immediately? Or is it worth buying Agree Realty?

Market confidence in the company’s operational model is further validated by its credit standing. In August, Fitch Ratings affirmed Agree Realty’s investment-grade status with an A- rating and stable outlook—a rarity within the REIT sector that underscores the company’s superior tenant quality and conservative financial management.

Insider Confidence and Robust Fundamentals

Recent insider activity provides additional insight into management’s perspective. A company director executed a meaningful purchase in early September, acquiring shares valued at over $54,000 at a price of $72.84 per share. This transaction serves as a notable vote of confidence in the company’s current valuation and future prospects.

The fundamental metrics supporting this optimism include:
– A diversified portfolio of 2,513 properties spanning all 50 U.S. states
– Strategic focus on investment-grade, recession-resistant tenants
– Substantial liquidity with approximately $2.3 billion in available capital
– Conservative leverage with a net debt-to-EBITDA ratio of just 3.1x

In an environment of economic uncertainty, Agree Realty’s emphasis on quality over quantity represents a distinct competitive advantage. The critical question for investors remains whether this defensive positioning will continue to deliver value through the next market cycle.

Ad

Agree Realty Stock: Buy or Sell?! New Agree Realty Analysis from March 25 delivers the answer:

The latest Agree Realty figures speak for themselves: Urgent action needed for Agree Realty investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from March 25.

Agree Realty: Buy or sell? Read more here...

Tags: Agree Realty
Robert Sasse

Robert Sasse

About Dr. Robert Sasse Accomplished economist, entrepreneur, and profound expert in financial markets. Dr. Robert Sasse holds a doctorate in economics and combines academic rigor with practical entrepreneurial experience. His deep expertise in economic relationships and unwavering conviction for a free-market liberal economic order drives his mission to provide investors with well-founded knowledge and guidance.
Areas of Expertise:
  • Economic Theory and Practice
  • Free-Market Economics
  • Entrepreneurship and Business Strategy
  • Investment Philosophy
Dr. Sasse's unique combination of academic knowledge and real-world business experience enables him to provide investors with comprehensive insights that bridge theory and practice.

Related Posts

ImmunityBio Stock
Analysis

Regulatory Rebuke Sends ImmunityBio Shares Tumbling

March 25, 2026
Realty Income Stock
Bonds

Realty Income’s Strategic Financing Defies High Interest Rate Environment

March 25, 2026
IBM Stock
Analysis

IBM Shares Face Pressure from Analyst Downgrades and Acquisition Concerns

March 25, 2026
Next Post
Alpine Immune Sciences Stock

Vertex Pharmaceuticals Secures Future Pipeline with $4.9 Billion Alpine Immune Sciences Acquisition

Rocket Lab USA Stock

Major Insider Selling at Rocket Lab Amidst Aggressive Growth Plans

AMD Stock

AMD Gains Strategic Advantage with China Market Reentry and Next-Gen AI Chips

Recommended

Thyssenkrupp Stock

Thyssenkrupp’s Restructuring Plan Faces Critical Test

1 week ago
Almonty Stock

Almonty’s Strategic Pivot: From Defense to Fusion Energy

2 months ago
Stride Stock

Stride Faces Investor Backlash Following Platform Failure

4 months ago
Finance_Commercial (2)

Cadre Holdings Announces Public Offering of Common Stock

2 years ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Bloom Energy Broadcom Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Oracle Palantir PayPal Plug Power QuantumScape Realty Income Robinhood Rocket Lab USA Salesforce Strategy Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Battalion Oil Navigates Debt and Operational Overhaul

Divergent Analyst Views Highlight Coeur Mining’s Strategic Transition

Rocket Lab Stock Attracts Bullish Analyst Sentiment Amid Growth Trajectory

TSMC’s Arizona Expansion Gains Momentum Amid Record Retail Investor Interest

Salesforce Shares Face Pressure from External AI Innovation

UnitedHealth Bets on Artificial Intelligence to Counteract Mounting Pressures

Trending

ImmunityBio Stock
Analysis

Regulatory Rebuke Sends ImmunityBio Shares Tumbling

by Rodolfo Hanigan
March 25, 2026
0

A significant regulatory warning from the U.S. Food and Drug Administration (FDA) has triggered a sharp sell-off...

Realty Income Stock

Realty Income’s Strategic Financing Defies High Interest Rate Environment

March 25, 2026
IBM Stock

IBM Shares Face Pressure from Analyst Downgrades and Acquisition Concerns

March 25, 2026
Battalion Oil Stock

Battalion Oil Navigates Debt and Operational Overhaul

March 25, 2026
Coeur Mining Stock

Divergent Analyst Views Highlight Coeur Mining’s Strategic Transition

March 25, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Regulatory Rebuke Sends ImmunityBio Shares Tumbling
  • Realty Income’s Strategic Financing Defies High Interest Rate Environment
  • IBM Shares Face Pressure from Analyst Downgrades and Acquisition Concerns

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com